QTI

8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

  QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today issued a mid-year 2026 letter to shareholders from its CEO, Dr. Raluca Dinu. The full text of the letter appears below and at this link which can be found on the QT Imaging website. Dear Fellow Shareholders, I am energized by QT Imaging’s many accomplishments so far in 2026, with impressive results by most any metric. Last week’s announcement of our second quarter financial results provides the catalyst for a review of the progress we’ve made, the foundation we’re building, and

10-Q - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

Second-quarter revenue reached $7.4 million; first-half revenue increased 116% to $14.0 million, with 28 scanners shipped Strengthened capital position through a $10.0 million public offering and expanded direct U.S. commercial capabilities to accelerate adoption Reaffirms full-year 2026 revenue guidance of approximately $39 million Conference Call begins at 4:30 p.m. Eastern Time today QT Imaging Holding, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three and six months ended June 30, 2026, and provided a b

4 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

3 - QT IMAGING HOLDINGS, INC. (0001844505) (Issuer)

QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that it will report financial results for the second quarter ended June 30, 2026, after market close on Wednesday, August 12, 2026, and will host a conference call beginning at 4:30 p.m. Eastern Time. Participants are encouraged to pre-register at the link below. Date: Wednesday, August 12, 2026 Time: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time Pre-registration: Link here. Callers who are unable to pre-register can access the conference call by dialing: United State

Appoints breast imaging industry veterans Jason Dyer as VP Regional Sales East and Dave Reinhart as VP Regional Sales West QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today advanced the direct U.S. commercial strategy for its Breast Acoustic CT™ Scanner with the appointment of Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West. Both executives joined QT Imaging in July 2026 and report to Satrajit Misra, the Company’s Chief Commercial Officer. "Building a direct U.S. commercial

S-8 - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

Dr. Albright brings more than 25 years of experience expanding markets and use cases across medical imaging, digital health, and oncology AI QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced the appointment of Julia Albright, Ph.D., as Chief Science Officer ("CSO"), effective July 27, 2026. Dr. Albright brings more than 25 years of experience spanning medical imaging, digital health, oncology, cloud technologies, and the development and commercialization of innovative healthcare technologies. As Chief Science Officer, sh

8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

QT Imaging Holdings, Inc. ("QT Imaging" or the "Company") (NASDAQ:QTI), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announced today that at the Annual Meeting of Company’s stockholders (the "Annual Meeting") held on July 28, 2026, the Company’s stockholders voted to approve (i) the election of Professor Zeev Weiner and Bryan Timm as Class II directors to serve until the Company’s 2029 Annual Meeting of Stockholders or until their respective successors are elected and qualified, (ii) the appointment of BPM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December

Regulatory approval enables commercialization of QT Imaging's technology in Israel and supports expansion of clinical research collaborations QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that the Israeli Ministry of Health has granted registration for the Company's scanner, authorizing commercialization of the system in Israel through February 2, 2028. The approval is based on the Company's existing U.S. FDA clearance and applicable Israeli regulatory requirements. QT Imaging’s Breast Acoustic CT™ Scanner produces t

FDA inspection outcome highlights the Company's robust Quality Management System, operational discipline, and commitment to the highest standards of quality QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in the research, development, and commercialization of innovative body imaging systems, announces the successful completion of its first routine inspection by the U.S. Food and Drug Administration (FDA), with zero Form 483 observations. The FDA inspection reviewed QT Imaging’s Quality Management System (QMS) and related processes that support the Company’s operations, with no Form 483 observations issued. The inspector also provi

DEF 14A - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

Dr. Raluca Dinu Participates in High-Profile Panels and Awards Ceremony Alongside Leading Healthcare Investors and Women’s Health Experts QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company engaged in the research, development and commercialization of innovative body imaging systems, announces that CEO Dr. Raluca Dinu presented the Shiftmaker Award to Martina Navratilova at the Sports Shiftmaker Awards ceremony last weekend and is participating in a series of thought-provoking women’s health panels during Wimbledon week in London. The panels and ceremony are hosted by The Shift, a mission-driven, intergenerational women's media platform backed

Multi-site study demonstrates less than 1% variability for Speed of Sound measurements and strong reproducibility across quantitative breast imaging biomarkersQT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported the characterization of repeatability and reproducibility metrics for quantitative biomarkers generated by its QT Imaging Breast Acoustic CTTM Scanner platform.As healthcare increasingly adopts quantitative imaging biomarkers to monitor disease, assess treatment response, and support clinical decision making, reproducibil

PRE 14A - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

Allows for Commercial Deployment of the Company's Radiation-Free Breast Imaging Technology Under Distribution Agreement with Gulf Medical Co. QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced that its Breast Acoustic CT™ scanner has received official classification and clearance from the Kingdom of Saudi Arabia (KSA) for use as a medical device in that country. The Saudi Food and Drug Authority (SFDA) approval allows QT Imaging's Breast Acoustic CT™ scanner to be marketed, sold, and deployed throughout Saudi Arabia, one

QT Imaging Holdings, Inc. (NASDAQ:QTI) ("QT Imaging" or the "Company"), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announces that it is expected to be added to the Russell Microcap® Index according to the list of additions posted online May 22, 2026. The addition of QT Imaging to this Index will be finalized at the conclusion of the 2026 Russell indexes reconstitution and, if affirmed, will be effective when the U.S. market opens on June 29, 2026. The June Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2026, ranked by total market capitalization. The Russell

8-K - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

QT Imaging Holdings, Inc. ("QT Imaging" or the "Company") (NASDAQ:QTI), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announced today the closing of its previously announced underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants in lieu thereof) for gross proceeds of approximately $10 million. Participants in this offering included current investors in QT Imaging as well as new investors. The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes. Ladenburg Thalmann & Co. Inc. acted as sole book-running manager a

424B5 - QT IMAGING HOLDINGS, INC. (0001844505) (Filer)

QT Imaging Holdings, Inc. ("QT Imaging" or the "Company") (NASDAQ:QTI), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, announced today the pricing of an underwritten public offering of 2,000,000 shares of common stock (or pre-funded warrants in lieu thereof) for gross proceeds of $10 million. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager and Northland Capital Markets is acting as co-manager for the offering. "This capital raise marks an important milestone for our company and reflects strong investor confidence in our strategy, execution, and long-term market opportunity," said Dr.